'''Leflunomid''' je [[Bolest-modifikujući antireumatik|DMARD]],<ref name="pmid15271770">{{cite journal |vauthors=Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P |title=When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? |journal=Annals of the rheumatic diseases |volume=64 |issue=1 |pages=44–51 |year=2005 |month=January |pmid=15271770 |pmc=1755199 |doi=10.1136/ard.2003.016709 |url=http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=15271770}}</ref> koji se koristi za tretiranje umerenog do jakog [[reumatoidni artritis|reumatoidnog artritisa]] i [[psorijatični artritis|psorijatičnog artritisa]]. On je [[Biosinteza pirimidina|inhibitor sinteze pirimidina]].<ref name="pmid17094333">{{cite journal |vauthors=Pinto P, Dougados M |title=Leflunomide in clinical practice |journal=Acta reumatológica portuguesa |volume=31 |issue=3 |pages=215–24 |year=2006 |pmid=17094333 |doi= |url=http://www.spreumatologia.pt/download_fich.php?path=pdfs&filename=ARP_2006_4_216_AR_-_Leflunomide.pdf}}</ref>
